Many problems on the treatment of depression with E.C.T. still exist, foremost among thembeing the prediction of the outcome of treatment. There is an extensive literature on prognostic factors, but these studies tend to be qualitative and impressionistic. There is a need for further investigation using all modem techniques of evaluation. In the papers by Dr. Hamilton and myself are presented a series of cases of depression who have been carefully studied clinically and closely followed-up after treatment with E.C.T., and in whom the clinical study and follow-up have been quantified by the use of a rating scale. The factors related to the outcome of treatment have been studied and an attempt made, in a group considered suitable for E.C.T. on general clinical grounds, to refine the indications for this treatment and to prognosticate more accurately its results.
The group studied comprised male in-patients who had been admitted to hospital with a depressive illness and who were considered likely to benefit from treatment with E.C.T. They had either attempted suicide before admission, or were considered serious suicidal risks, or could not be dealt with as out-patients because of the intensity of their symptoms or for social reasons, or in a small number of cases because of suspected or confirmed physical illness which required preliminary hospital care.
The outcome of treatment was then correlated with certain factors in the general clinical data. These included the family history, neurotic traits in childhood, neurotic traits in adult life, the mode of onset (sudden or gradual), the course of the illness (progressive or fluctuating), the duration of illness, physical and psychological precipitant factors, the number of previous attacks, diurnal variation, age, weight, Rees-Eysenck body index, blood pressure, Funkenstein test and Hobson score.
Of the 64 patients in this series, 13 did not receive E.C.T. for various reasons. Of these 13, 2 committed suicide, and only 5 recovered fully. 51 patients received E.C.T., the average course comprising 6 treatments. 43 recovered and were discharged from hospital, and one com-AUGUST mitted suicide. Contrasting the fully recovered with the rest, a statistical comparison of the treated and untreated groups showed the more favourable outcome in the former as highly significant (X2=11 6, d.f.=1, P<0O001). However, of the 43 patients who responded satisfactorily to E.C.T., 15 relapsed. They recovered after a further course ofE.C.T. and remained well.
The patients who did not do well with E.C.T., with one exception, tended to form a homogeneous group. All but one were in the higher agegroup. All were cases of severe endogenous depression. One could not say that this clinical picture was necessarily related to the poor outcome with E.C.T. as many other patients with endogenous depression showed good results. However, the principal failures were found in this group. 16 variables were correlated with outcome, and in only 4 was a significant relationship confirmed. The highest correlation was that of duration of illness (046), followed by weight (-0-31) and the body index (029). The findingsfor the Funkenstein test also showed a significant correlation with outcome. Age and blood pressure, usually accepted as influencing the outcome with E.C.T., showed in fact very low correlations. The Hobson score gave a low correlation with outcome (018). This score consists of 16 items which assess certain factors related to personality, intelligence and the development and symptoms of the illness. In Hobson's original paper (1953) a low score was highly correlated with a good response to treatment. Our findings did not confirm those originally reported. This may have been due to the difficulty we found in applying this tool, full and accurate information on which is difficult to elicit.
Many features of interest have emerged from this study. The clinical findings emphasize the value of E.C.T. Those with a history of short duration and pyknic body build and heavy body weight appear to do best with this treatment. Since even severe cases of endogenous depression may remit spontaneously over a period of some months, it is certainly worth waiting to see if spontaneous remission will develop when the administration of E.C.T. would involve a considerable danger to the life of the patient.
(Illustrative cases quoted.) The fact that our failures were mainly in the severe endogenous depression group is of interest and indicates that such features are not necessarily indicative of good prognosis as is generally assumed. The suicide in the treated group was unexpected and preceded by previous suicidal attempts of histrionic quality. 2 patients who had morbid fear of E.C.T., and who had previously refused to accept this treatment, committed suicide after ultimate acceptance of the treatment and before it could begin. I have little doubt that in these cases fear of E.C.T. acted as a powerful precipitant towards suicide.
Many difficulties arose in the course of this investigation. Our follow-up system worked imperfectly and did not take into account the fluctuations of the illness and the high incidence of relapses. To eliminate this problem the patients have been seen at more frequent intervals over a longer period. It is possible that the high incidence of relapse is related to the number of treatments initially given. It 
Dr. Max Hamilton (Leeds): Autonomic Function and Syndromes in Depression
Dr. White's paper gave an account of the relation between various factors in the patient's history and the outcome of treatment in depression. The present paper is concerned with the details of two of these factors.
Investigation of autonomic functions in relation to psychiatry has a long history, but in recent years interest has been concentrated chiefly on the Funkenstein test. As originally described, the test consists of graphing the changes in blood pressure which occur, first, after the intravenous injection of 0 025 mg. of adrenaline, and then, when the blood pressure has returned to its basal level, after the intramuscular injection of 10 mg. of Mecholyl, recorded for no longer than twenty-five minutes. Funkenstein and his colleagues (1952) classified the curves so obtained into 7 groups, and on the basis of their findings announced that Groups VI and VII had a good prognosis to treatment by E.C.T., regardless of the diagnosis of the patient. In recent years, it has been customary to omit the adrenaline, since it is not very informative. This has the effect of amalgamating Groups II and III, and V and VI.
Considering only the curves obtained after the injection of Mecholyl, Gellhorn (1953) classified the curves into those showing hyper-, normo-, and hypo-reactivity. He stated that the hypo-reactive curves indicated a good prognosis after treatment.
Two difficulties arise: In the first place, a fair proportion of curves do not fit the classifications, and in the second (as shown by Munro, 1958) , this method of classification has a good deal of unreliability, so that errors of classification form a large proportion of the total.
A new approach to the problem was attempted by the method of curve-fitting. The most appropriate curves to use would probably be either an exponential curve, comparable to the changes of temperature of a cold body in a warm room, or some form of cybernetic function. TUnfortunately, for various reasons these are impracticable. In the end, it was decided that the simplest curve of all, i.e. a straight line, might give satisfactory results. The use of the bestfitting straight line converts the information in the Funkenstein curve into three parameters: Basal blood pressure, the drop of blood pressure, and the slope of the line. The first two are highly reliable measures with reliability coefficients of 0O80 and 075 respectively. The slope is unreliable, having a coefficient of 0-36. Since both the Funkenstein and Gellhorn classifications depend much on the slope of the curve, this accounts for the unreliability of classification.
The correlation between outcome after treatment and basal blood pressure is-0 -11, and with drop is 0-26. The multiple correlation of both with outcome is 027 and this is statistically significant. It has recently been pointed out that the Funkenstein curve tends to change with age, and it has been suggested that its relation with outcome after treatment is essentially a function of age. I have found that the addition of age to the multiple correlation raises it to 0-28, a negligible increase.-Thus the Funkenstein test is providing information which is independent of age. By itself, age has a correlation of 0.10 with outcome after treatment.
It has been possible to quantify the relationship between outcome after treatment and the Funkenstein test and other variables, because we have been using a specially devised rating scale which contains 17 variables. The inter-correlations between these variables have been calculated and latent roots and vectors obtained. The first vector (factor) corresponds fairly obviously with that of endogenous depression. The second corresponds, but not so well, with that of reactive depression. (It must be remembered that factors can never truly correspond with diagnostic categories.) The third factor does not correspond with any recognizable clinical syndrome, but it does have significant correlation with outcome, and it is the only one that has. The fourth factor does not correspond with any obvious clinical syndrome, but on investigating the case histories of those patients who score high in this factor, it is seen that they have abnormal, inadequate, asocial personalities. (At this point three typical case histories were reported.)
The relation between outcome after treatment and factor measurement is as follows: F1 023, F2 017, F3 027, F4 -009. The five highest correlations between outcome and variables investigated are as follows: Length of history 046, weight -0-31, body index (Rees-Eysenck) 029, the initial score on rating scale 0-28, Funkenstein drop 026. These are not high, but in view of the smallness of the inter-correlations, it is not surprising that the multiple correlation between these five variables and outcome after treatment is 062. This is about as high as is ever obtained in the field of research on personality, although it must be pointed out that it is not very helpful for prediction of the outcome for any individual patient.
The results obtained so far are interesting, but need to be interpreted with caution. The correlation between the variables investigated and outcome after treatment is low, but this is due partly to the careful selection of patients and partly to the post-treatment fluctuations of the patients' condition. The problem of relapses and recurrences is clearly related to that of giving an appropriate dose of E.C.T., and until this problem is settled little further increase in these correlations is to be expected. It is of interest that three of the "predictor" variables are concerned with physiological and constitutional measurements.
The quantitative assessment of the Funkenstein test shows that its relation to outcome is small. The test is of little practical value at the moment, but it is of considerable theoretical interest and needs further development.
This investigation can be summarized as follows: the Funkenstein test has been dissected into reliable and unreliable variables and the former have been proved to show a relation to outcome, albeit a small one. The use of a specially designed rating scale has given quantified relationships with outcome, and also suggested that a particular group of symptoms is related to an. abnormal type of personality. Finally, the multiple correlation with outcome has indicated the importance of constitutional factors. Iproniazid in the Treatment of Depression Much of the interest in iproniazid stems from the fact that its use in the treatment of depression followed logically from data acquired from animal experimentation.
In the experimental animal it has been shown that changes in the brain concentration of 5hydroxytryptamine (5-HT) and catechol amines are associated with alterations in the behaviour of the animal. Thus, the decrease in brain concentrations of these substances obtained after treatment with reserpine results in behaviour compatible with a state of depression 03rodie Carlsson et al., 1958) whilst an increase, obtained by administration of a precursor substance, leads to excitement (Bogdanski et al., 1958; Carlsson et al., 1958) . Iproniazid has a marked inhibitory effect on mono-amine oxidase, the enzyme largely responsible for the inactivation of 5-HT (Sjoerdsma et al., 1955) . A proportion of the naturally occurring catechol amines are also inactivated by this mechanism (Leeper et al., 1958) . By virtue of this action on mono-amine oxidase, iproniazid leads to increased brain concentrations of 5-HT and catechol amines and again this is associated with a state of excitement (Spector et al., 1958) .
In man, reserpine has a tendency to induce a state of depression and also liberates 5-HT from its binding sites in platelets (Carlsson et al., 1957) although there have been no direct observations on brain tissue. Conversely, iproniazid, which may cause euphoria, gives rise to increased concentrations of 5-HT in human platelets (Pletscher and Bernstein, 1958) .
Although there is no evidence to suggest that the depressive illnesses seen in clinical practice are due to a deficiency of 5-HT or catechol amines, it is not unreasonable to postulate that any improvement obtained with iproniazid may be connected with altered concentrations of these substances. The present investigation was, therefore, designed to answer the following questions: (1) Does iproniazid benefit patients with depression? (2) If so, can the patients who respond be differentiated clinically or biochemically from those who do not? -(3) In patients who respond to iproniazid, is the benefit due to changes in the concentrations in the brain of 5-HT or of catechol amines?
Method.-50 patients with depression who had been considered suitable for E.C.T. were given iproniazid in doses up to 450 mg./day for periods varying from two to forty weeks. Placebo was also used. The degree of depression was assessed by weekly rating scales which were completed by the junior psychiatrist in charge of the case who was unaware when placebo tablets were being used. Patients were said to respond to iproniazid (3) In patients who respond to iproniazid, is the if the depression improved with treatment, benefit due to changes in the concentrations in the relapsed when placebo was substituted and imbrain of5-HTor ofcatechol amines? In animals, proved again when iproniazid was reintroduced. 5-hydroxytryptophan (5-HTP) and 3, 4-Patients who improved with iproniazid but did dihydroxyphenylalanine (DOPA) are known to not relapse when placebo was substituted had increase the brain concentrations of 5-HT and necessarily to be designated as "coincidental" catechol amines respectively (Udenfriend et al., improvement. 1957; Carlsson et al., 1958) . This method, unsatisfactory from some points Patients who were known to "respond to of view, was sufficiently elastic for use with a new iproniazid" were given DL-5-HTP and DLdrug where such things as dosage and the time DOPA by intravenous injection at intervals of at elapsing prior to any improvement were insufficileast a day, at the same time of the day and in ently known. More important, it ensured the random order. Three patients were given the selection of a group of patients known to respond drug in a single dose of 12-5 mg. while receiving to iproniazid and equally important, a group who, iproniazid but during the period of therapy before because of a prolonged course of treatment, could improvement was expected. Three patients be definitely assessed as having failed to respond. were given the drug in the absence of iproniazid.
Results.-(1) Does iproniazid benefit patients In this group the dosage ranged from 25 mg. of with depression? The results are shown in of 12-5 mg. of each subcutaneously twice daily improved, whether "coincidentally" or in "refor sixteen days. No improvement in the sponse to iproniazid" the 52% improvement depression was noted clinically. compares closely with that reported by other Any relief from depression was bought at the workers (Symposium on Iproniazid, 1958) . The price of side-effects which were pronounced and improvement in patients defined as having frequent. One patient developed jaundice ten "responded to iproniazid" usually commenced days after stopping iproniazid and died from during the second or third weeks of treatment and acute hepatic necrosis thirty-three days after this delay was not shortened by increasing the stopping the drug. When we became aware of dose of the drug. There appeared to be no the danger of liver damage, "standard tests of advantage in giving iproniazid in doses greater liver function" were carried out routinely in 24 than 200 mg./day. On the other hand, some patients. Serum bilirubin, thymol turbidity, patients relapsed on dosage lower than 150 mg./ zinc sulphate turbidity, alkaline phosphatase and day. There was no evidence that iproniazid cuts serum proteins showed no significant abnormshort a depressive illness, but rather that it ality. Serum glutamic-oxalo-acetic transaminase provides symptomatic relief for as long as the (G.-O.T.) activity, which has recently come into drug is continued.
extensive use as an index of hepatocellular (2) Can the patients who respond be differentidamage, was also carried out in 29 patients. (For ated clinically or biochemically from those who do methods see Pare and Sandler, 1959b.) Values not? We were unable to differentiate clinically were within normal limits of 8-28 units/ml. at those patients who would be expected to improve 200 C. in all sera prior to drug treatment. In 9 with iproniazid from those who would not. There patients levels above the normal range, up to 140 was a suggestion that patients who "responded to units/mil., were found during iproniazid adminisiproniazid" had pre-treatment values for urinary tration. On stopping the drug the levels gradu-5-hydroxyindoleacetic acid (5-HIAA) which ally dropped, taking about four to six weeks to were lower than those in patients who did not return to normal. There did not appear to be respond (Table II) .. 45±0-75 findings must be considered. Although the 7 patients who improved "comicidentally" with iproniazid therapy 3-1±0-86 P>01 iterpretation is difficult, we would suggest that any rise detected in routine weekly serum G.-O.T. estimations should, in the present state of our knowledge, be treated as presumptive evidence of early liver damage and that the drug be discontinued.
Conclusions.-Perhaps of most interest is the question whether iproniazid is a general euphoriant or whether it acts only on those patients whose depression is due to a specific metabolic abnormality which has yet to be identified. The striking response to iproniazid noted in some patients compared with the apparent ineffectiveness of the drug in others suggests that the latter may be true. Certainly it did appear that, prior to treatment, there was a lower turnover of 5hydroxyindole metabolism, as judged by the urinary excretion of 5-HIAA, in patients who subsequently responded to iproniazid, compared with patients who did not respond. On the other hand, neither parenteral 5-HTP nor DOPA, in the dosage used, resulted in any symptomatic improvement and it may be that other amines reported to be affected by mono-amine oxidase inhibitors are of importance (Udenfriend, 1959) .
Be that as it may, the present position is that iproniazid is providing an enormous stimulus to the development of a rational chemotherapy of depression. While it is to be hoped that future amine oxidase inhibitors will be free of hepatotoxic effects, the use of iproniazid in clinical prac-tice should always be carefully considered, and, if used, accompanied by weekly serum G.-O.T. estimations.
